samedan logo

 
 
spacer
home > pmps > spring 2019 > the case for blockchain technology
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Case for Blockchain Technology

Current pharmaceutical supply chain spending is estimated to be US $230 billion, representing about 25% of total costs. Looking into the future, the biggest impact on revenue and earnings before interest and taxes growth is set to occur through the digitisation of supply chains, but, unfortunately, only 2% of executives report that supply chains are the focus of their forward-looking digital strategies (1). Additionally, with an increasingly complex supply chain, pharma manufacturers are outsourcing work to contract packaging organisations (CPOs) and CMOs at a greater rate than has been observed in the past. As a result, collaboration and visibility is critical for these relationships to work well.

According to discussions with heads of supply chain and IT at eight of the 15 largest pharma companies by global revenue, sharing of critical documents and drug provenance as products move through the supply chain is an area where improved cross-supply chain collaboration is critical. For example, the mishandling of documents and delays in the documentation and approvals process can create significant costs to pharma companies, measured in days or weeks of lead time and millions of dollars in avoidable cost.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jason Lacombe is the CEO of Veratrak, a software company purpose built for the pharma supply chain, facilitating secure document and master data collaboration for its partners. He first became interested in blockchain technology while studying for his PhD at the University of Oxford, UK, where he held an executive role on the blockchain society. In a past life, Jason had exposure to the pharma industry as an Expert Advisor to the European Parliament, member of a WHO collaborating centre, and as a Health Economist. Most recently, he was selected for the Forbes 30 Under 30 list and as a blockchain influencer in a report led by the UK All Party Parliamentary Group on blockchain.
spacer
Jason Lacombe
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Fujifilm Invests $188 Million in New Cell Culture Media Manufacturing Facility

TOKYO, November 22, 2022 – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA. The new site will be operated by FUJIFILM Irvine Scientific, Inc., a subsidiary of FUJIFILM Corporation, and a world leader in the development and manufacture of advanced cell culture solutions for life science research, bioproduction, cell therapy manufacturing, and medical applications. The new facility is planned to ensure that FUJIFILM Irvine Scientific can meet increasing market demands for high quality cell culture media solutions.
More info >>

White Papers

Tightening Your Supply Chain Against Counterfeits

World Courier

As today’s global pharmaceutical supply chain grows increasingly longer and more complex, each link provides added opportunity for counterfeiters. While pending regulatory changes promise to tighten the supply chain with respect to production and distribution entities and new packaging technologies will make the identification of counterfeit products easier, the logistics of global distribution remains a weak link. How can the pharmaceutical shipper ensure the security of the supply chain over thousands of miles and extended periods of time when the product is no longer in his possession?
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement